CD33 ‐directed immunotherapy with third‐generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and CD33 ‐edited acute myeloid leukemia and hematopoietic stem and progenitor cells-Reference-Cited by-同舟云学术

CD33 ‐directed immunotherapy with third‐generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and CD33 ‐edited acute myeloid leukemia and hematopoietic stem and progenitor cells

Published:2021-11-23 Issue:7 Volume:150 Page:1141-1155
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Intl Journal of Cancer

Author:

Liu Yi¹²^ORCID,Wang Sanmei¹³,Schubert Maria‐Luisa¹,Lauk Annika¹,Yao Hao¹,Blank Maximilian Felix¹,Cui Chunhong¹⁴,Janssen Maike¹,Schmidt Christina¹,Göllner Stefanie¹,Kleist Christian⁵,Zhou Fengbiao¹,Rahfeld Jens‐Ulrich⁶,Sauer Tim¹,Schmitt Michael¹^ORCID,Müller‐Tidow Carsten¹²

Affiliation:

1. Department of Medicine V Heidelberg University Hospital Heidelberg Germany

2. Molecular Medicine Partnership Unit (MMPU) European Molecular Biology Laboratory (EMBL) and Heidelberg University Hospital Heidelberg Germany

3. Department of Hematology First Affiliated Hospital of Nanjing Medical University, Collaborative Innovation Center for Cancer Personalized Medicine Nanjing China

4. Shanghai University of Medicine and Health Sciences Shanghai China

5. Department of Nuclear Medicine Heidelberg University Hospital Heidelberg Germany

6. Fraunhofer Institute for Cell Therapy and Immunology IZI Halle Germany

Funder

Deutsche Forschungsgemeinschaft

Deutsche Krebshilfe

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.33865

Reference59 articles.

1. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

2. Clonal selection with RAS pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid;McMahon CM;Leukemia,2019

3. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207997s000lbl.pdf

4. https://www.ema.europa.eu/en/documents/product-information/rydapt-epar-product-information_en.pdf

5. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211349s000lbl.pdf

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chimeric Antigen Receptor T-Cell Therapy in Acute Myeloid Leukemia: State of the Art and Recent Advances;Cancers;2023-12-20

2. Efficient long-term multilineage engraftment of CD33-edited hematopoietic stem/progenitor cells in nonhuman primates;Molecular Therapy - Methods & Clinical Development;2023-12

3. Broadening the horizon: potential applications of CAR-T cells beyond current indications;Frontiers in Immunology;2023-11-27

4. Proteomic profiling identifies Serpin B9 as mediator of resistance to CAR T-cell and bispecific antibody treatment in B-cell lymphoma;2023-06-28

5. Clinical development of chimeric antigen receptor-T cell therapy for hematological malignancies;Chinese Medical Journal;2023-06-23